OOIR: Observatory of International Research

Papers

(The TQCC of Experimental Hematology & Oncology is 14. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-07-01 to 2024-07-01.)

Article	Citations
Complex roles of cAMP–PKA–CREB signaling in cancer	225
CD44 as a tumor biomarker and therapeutic target	190
Risk factors and outcome of COVID-19 in patients with hematological malignancies	112
Research progress on dendritic cell vaccines in cancer immunotherapy	71
Role of m6A writers, erasers and readers in cancer	70
Engineering better chimeric antigen receptor T cells	67
SARS-CoV-2 induced thrombocytopenia as an important biomarker significantly correlated with abnormal coagulation function, increased intravascular blood clot risk and mortality in COVID-19 patients	66
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC	65
A global, regional, and national survey on burden and Quality of Care Index (QCI) of hematologic malignancies; global burden of disease systematic analysis 1990–2017	63
YTHDF1 promotes hepatocellular carcinoma progression via activating PI3K/AKT/mTOR signaling pathway and inducing epithelial-mesenchymal transition	60
Heterogeneity of the tumor immune microenvironment and its clinical relevance	59
Roles of tumor-associated macrophages in tumor progression: implications on therapeutic strategies	58
Macrophage, the potential key mediator in CAR-T related CRS	55
MiRNA-mediated EMT and CSCs in cancer chemoresistance	52
Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment	51
Breast cancer heterogeneity and its implication in personalized precision therapy	50
AP-1 family transcription factors: a diverse family of proteins that regulate varied cellular activities in classical hodgkin lymphoma and ALK+ ALCL	47
Recent advances and challenges of bispecific antibodies in solid tumors	46
VEXAS syndrome in myelodysplastic syndrome with autoimmune disorder	43
Targeting PD-1/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia	41
COVID-19 vaccination associated severe immune thrombocytopenia	38
Current insight into the regulation of PD-L1 in cancer	38
Blocking siglec-10hi tumor-associated macrophages improves anti-tumor immunity and enhances immunotherapy for hepatocellular carcinoma	37
Natural killer cells associated with SARS-CoV-2 viral RNA shedding, antibody response and mortality in COVID-19 patients	36
Leukemia stem cell-bone marrow microenvironment interplay in acute myeloid leukemia development	36

PCSK9 promotes tumor growth by inhibiting tumor cell apoptosis in hepatocellular carcinoma	34
Progress in understanding the mechanisms of resistance to BCL-2 inhibitors	33
Etanercept as a new therapeutic option for cytokine release syndrome following chimeric antigen receptor T cell therapy	33
TRIM family contribute to tumorigenesis, cancer development, and drug resistance	33
m6A binding protein YTHDF2 in cancer	33
Exosomes from BM-MSCs promote acute myeloid leukemia cell proliferation, invasion and chemoresistance via upregulation of S100A4	33
Increasing cure rates of solid tumors by immune checkpoint inhibitors	31
Pan-cancer analysis reveals tumor-associated macrophage communication in the tumor microenvironment	30
TCR engineered T cells for solid tumor immunotherapy	30
The role of neutrophil extracellular traps in cancer progression, metastasis and therapy	30
Belinostat in combination with standard cyclophosphamide, doxorubicin, vincristine and prednisone as first-line treatment for patients with newly diagnosed peripheral T-cell lymphoma	30
Recent advances in Lynch syndrome	29
Roles of the intestinal microbiota and microbial metabolites in acute GVHD	29
MET amplification identified by next-generation sequencing and its clinical relevance for MET inhibitors	29
The global, regional, and national burden of kidney cancer and attributable risk factor analysis from 1990 to 2017	29
Correlation of mutational landscape and survival outcome of peripheral T-cell lymphomas	24
Understanding the versatile roles and applications of EpCAM in cancers: from bench to bedside	24
Distinction between clonal and paraclonal cutaneous involvements in VEXAS syndrome	23
The frequency and inter-relationship of PD-L1 expression and tumour mutational burden across multiple types of advanced solid tumours in China	22
Advances of target therapy on NOTCH1 signaling pathway in T-cell acute lymphoblastic leukemia	22
Gut fungi enhances immunosuppressive function of myeloid-derived suppressor cells by activating PKM2-dependent glycolysis to promote colorectal tumorigenesis	22
Myeloid-derived suppressor cells in hematologic malignancies: two sides of the same coin	22
A comprehensive model to predict severe acute graft-versus-host disease in acute leukemia patients after haploidentical hematopoietic stem cell transplantation	22
Expression differences of miR-142-5p between treatment-naïve chronic myeloid leukemia patients responding and non-responding to imatinib therapy suggest a link to oncogenic ABL2, SRI, cKIT and MCL1 si	22
Comprehensive analysis of clinical, pathological, and genomic characteristics of follicular helper T-cell derived lymphomas	22
Molecular drivers and cells of origin in pancreatic ductal adenocarcinoma and pancreatic neuroendocrine carcinoma	21
Tumor mutation burden estimated by a 69-gene-panel is associated with overall survival in patients with diffuse large B-cell lymphoma	21
Spindle and kinetochore-associated complex subunit 3 could serve as a prognostic biomarker for prostate cancer	21
IPSS-M has greater survival predictive accuracy compared with IPSS-R in persons ≥ 60 years with myelodysplastic syndromes	20
Trends in disease burden of chronic myeloid leukemia at the global, regional, and national levels: a population-based epidemiologic study	20
A novel and efficient CD22 CAR-T therapy induced a robust antitumor effect in relapsed/refractory leukemia patients when combined with CD19 CAR-T treatment as a sequential therapy	20
Circulating RNA biomarkers in diffuse large B-cell lymphoma: a systematic review	20
p53 amyloid aggregation in cancer: function, mechanism, and therapy	19
Serologic response and safety of COVID-19 vaccination in HSCT or CAR T-cell recipients: a systematic review and meta-analysis	19
Chimeric antigen receptor-engineered NK cells: new weapons of cancer immunotherapy with great potential	19
Novel treatment combining antiviral and neutralizing antibody-based therapies with monitoring of spike-specific antibody and viral load for immunocompromised patients with persistent COVID-19 infectio	19
Atezolizumab plus bevacizumab combination enables an unresectable hepatocellular carcinoma resectable and links immune exclusion and tumor dedifferentiation to acquired resistance	19
Learn from antibody–drug conjugates: consideration in the future construction of peptide-drug conjugates for cancer therapy	18
Tanshinone IIA attenuates the stemness of breast cancer cells via targeting the miR-125b/STARD13 axis	18
Modified dendritic cell-derived exosomes activate both NK cells and T cells through the NKG2D/NKG2D-L pathway to kill CML cells with or without T315I mutation	18
Role of the lectin pathway of complement in hematopoietic stem cell transplantation-associated endothelial injury and thrombotic microangiopathy	18
Hypoxia-associated circPRDM4 promotes immune escape via HIF-1α regulation of PD-L1 in hepatocellular carcinoma	18
The degree of microsatellite instability predicts response to PD-1 blockade immunotherapy in mismatch repair-deficient/microsatellite instability-high colorectal cancers	18
Identification of potential resistance mechanisms and therapeutic targets for the relapse of BCMA CAR-T therapy in relapsed/refractory multiple myeloma through single-cell sequencing	17
RHO GTPase family in hepatocellular carcinoma	17
Targeting metabolic reprogramming in chronic lymphocytic leukemia	17
The metabolic adaptation mechanism of metastatic organotropism	16
Fecal microbiota transplantation combined with ruxolitinib as a salvage treatment for intestinal steroid-refractory acute GVHD	16
SEPHS1 promotes SMAD2/3/4 expression and hepatocellular carcinoma cells invasion	16
Function and clinical significance of N6-methyladenosine in digestive system tumours	16

Molecular insights into pathogenesis and targeted therapy of peripheral T cell lymphoma	16
ALKBH5 prevents hepatocellular carcinoma progression by post-transcriptional inhibition of PAQR4 in an m6A dependent manner	16
Targeting phosphoinositide 3-kinases and histone deacetylases in multiple myeloma	15
Recent updates for antibody therapy for acute lymphoblastic leukemia	15
Platelet-driven coagulopathy in COVID-19 patients: in comparison to seasonal influenza cases	15
Matching-adjusted indirect treatment comparison of chimeric antigen receptor T-cell therapies for third-line or later treatment of relapsed or refractory large B-cell lymphoma: lisocabtagene maraleuce	15
Current approaches to develop “off-the-shelf” chimeric antigen receptor (CAR)-T cells for cancer treatment: a systematic review	15
CD7-directed CAR T-cell therapy: a potential immunotherapy strategy for relapsed/refractory acute myeloid leukemia	14
The role of organoids in cancer research	14
A pan-cancer analysis of the oncogenic role of leucine zipper protein 2 in human cancer	14
CD44 promotes hepatocellular carcinoma progression via upregulation of YAP	14
Increased TOX expression associates with exhausted T cells in patients with multiple myeloma	14
Applications of gut microbiota in patients with hematopoietic stem-cell transplantation	14
METTL3 modulates m6A modification of CDC25B and promotes head and neck squamous cell carcinoma malignant progression	14
New insights into epigenetic regulation of resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms and therapeutic opportunities	14
Frontiers in the COVID-19 vaccines development	14
New insight into circRNAs: characterization, strategies, and biomedical applications	14
CD47xCD19 bispecific antibody triggers recruitment and activation of innate immune effector cells in a B-cell lymphoma xenograft model	14
Ferroptosis: a novel regulated cell death participating in cellular stress response, radiotherapy, and immunotherapy	14